In humans, ADRB3 deficiency has been associated with an increased risk of developing cardiovascular diseases and obesity [19]. Therefore, like POMC and NPY, altering the methylation status of ADRB3 by therapeutic agents is another excellent candidate for continued research in the efforts against obesity. The gene discussed is POMC; the disease is obesity due to melanocortin 4 receptor deficiency.